Form 4: Mirum Pharmaceuticals Director Saira Ramasastry Executes Stock Option and Sells Shares

Director Saira Ramasastry of Mirum Pharmaceuticals exercised stock options and sold 5,000 shares of common stock on June 5, 2024.

Summary

• On June 5, 2024, Saira Ramasastry, a director at Mirum Pharmaceuticals, exercised a stock option to acquire 5,000 shares of common stock at a price of $14.12 per share.
• Simultaneously, Ramasastry sold 5,000 shares of common stock at a price of $25.68 per share.
• Following these transactions, Ramasastry no longer directly owns any common stock.
• Ramasastry also acquired 8,779 stock options with an exercise price of $26.30, vesting fully by the company's 2025 annual stockholder meeting.
• Additionally, 5,703 restricted stock units (RSUs) were acquired, each representing a contingent right to receive one share of common stock, also vesting fully by the 2025 annual stockholder meeting.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there's insider selling, the acquisition of new options and RSUs suggests continued confidence. The sale is a small percentage of the outstanding shares.

Positives

• The acquisition of stock options and restricted stock units indicates continued alignment with the company's long-term success.

Negatives

• The sale of 5,000 shares could be interpreted negatively by some investors, although it is a relatively small transaction.

Risks

• There are no specific risks highlighted in this document, but insider selling can sometimes create negative market sentiment.

Future Outlook

The vesting of stock options and restricted stock units is tied to the first anniversary of the grant date, but will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how the market interprets the insider selling.

Key Dates